相邻的脑膜瘤与B细胞淋巴瘤:范围综述与病例示例
该范围综述系统检索OVID Medline和PubMed数据库,纳入9例相邻同时性脑膜瘤与B细胞淋巴瘤病例报告(含本机构1例)。诊断时平均年龄67.4岁,女男比7:2,100%病例术后才确诊同时性颅内肿瘤。接受辅助化疗者(n=5)中位无进展生存期12个月(范围3-18个月),未接受者(n=2)中位2个月(范围1-3个月)。
要点
- 相邻同时性脑膜瘤与B细胞淋巴瘤罕见,100%病例术后才确诊同时性肿瘤。
- 所有脑膜瘤均为组织病理学I级,淋巴瘤以弥漫大B细胞淋巴瘤为主(56%)。
- 接受辅助化疗者(n=5)中位无进展生存期12个月,未接受者(n=2)中位2个月。
核心结论
- 相邻同时性脑膜瘤与B细胞淋巴瘤罕见,影像上可能表现为不显眼的孤立性颅内肿瘤。
- 基于有限病例及当前淋巴瘤治疗,无进展生存期可能取决于及时启动针对淋巴瘤的化疗而非脑膜肿块的手术切除。
- 作者认为,医务人员应优先进行及时的医疗管理。
研究设计与样本
- 范围综述,遵循PRISMA指南系统检索OVID Medline和PubMed数据库。
- 仅纳入相邻同时性脑膜瘤与B细胞淋巴瘤的人类临床报告,共9例病例报告符合标准(含本机构1例示例病例)。
主要发现
- 诊断时平均年龄67.4岁,女性与男性比例为7:2。
- 100%病例在手术切除后才怀疑或发现同时性颅内肿瘤诊断。
- 所有脑膜瘤组织病理学诊断均为I级。
- 淋巴瘤分布为弥漫大B细胞淋巴瘤56%、转移性淋巴瘤22%、Burkitt淋巴瘤11%、滤泡性淋巴瘤11%。
- 所有患者均接受手术切除;接受辅助化疗者(n=5)中位无进展生存期12个月(范围3-18个月),未接受者(n=2)中位2个月(范围1-3个月)。
临床怎么用
- 作者认为,医务人员应优先进行及时的医疗管理。
- 作者认为,无进展生存期可能取决于及时启动针对淋巴瘤的化疗而非脑膜肿块的手术切除。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The diagnosis of a contiguous, synchronous meningioma and central nervous system B-cell lymphoma is rare and associated with paradoxical treatment paradigms. We performed a scoping review of contiguous meningioma and B-cell lymphoma and included an additional illustrative case. METHODS: The OVID Medline and PubMed databases were systematically searched using the Preferred Reporting Items of Systematic Reviews and Meta-Analysis guidelines. Only human clinical reports of contiguous, synchronous meningioma and B-cell lymphoma were included. We concurrently detailed a representative case from our institution. RESULTS: Nine case reports met our criteria, including the present case. The average age at diagnosis was 67.4 years. Patients showed a female-to-male predominance of 7:2. The diagnosis of synchronous intracranial tumors was not suspected or discovered until after surgical resection in 100% of cases. All meningiomas were grade I on histopathologic diagnosis, while lymphomas were distributed between diffuse large B-cell lymphoma (56%), metastatic lymphoma (22%), Burkitt lymphoma (11%), and follicular lymphoma (11%). All patients underwent surgical resection. Patients (n = 5) treated with adjuvant chemotherapy had evidence of longer progression-free survival (median 12 months; range, 3-18 months) than patients without adjuvant chemotherapy (n = 2; median 2 months; range, 1-3 months). CONCLUSIONS: Contiguous, synchronous meningioma/B-cell lymphoma is a rare diagnosis that may appear as an inconspicuous solitary intracranial neoplasm on imaging. Based on the limited cases and current treatment of lymphoma, progression-free survival may be contingent on the prompt initiation of chemotherapy targeting the lymphoma rather than surgical resection of the meningeal mass. Providers should prioritize prompt medical management.
引用
- Hicks WH, Pernik MN, Adeyemo E, et al. Contiguous Meningioma and B-Cell Lymphoma: A Scoping Review and Case Illustration. World Neurosurg. 2021. PMID: 34798339. doi:10.1016/j.wneu.2021.11.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。